Shots:    U.S. tariff shifts are forcing pharma manufacturers to accelerate reshoring, reduce duty exposure, and stabilize pricing, fueling renewed investment in onshore final manufacturing, Most Favored Nation pricing strategies, and selective direct-to-consumer pilots to secure tariff relief amid policy volatility  As pricing, reimbursement, market access, and trade regulations evolve, companies are prioritizing late-stage, lower-risk…